Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma
- 19 September 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 63 (3) , 315-321
Abstract
Aims: To determine whether lower umbilical cord than maternal binding of indinavir and saquinavir contributed to the low cord : maternal (C : M) total concentration ratios reported previously.Methods: Indinavir and saquinavir unbound fraction (fu) was determined using equilibrium dialysis. Buffer solutions of human serum albumin (HSA) (20.0, 30.0, 40.0 g l−1) and α1‐acid glycoprotein (AAG) (0.20, 0.60, 2.00 g l−1) were spiked with indinavir (1.00 and 8.00 mg l−1) or saquinavir (0.15 and 1.50 mg l−1). Matched maternal and umbilical cord plasma was spiked with 1.00 mg l−1 indinavir (n = 12) or 0.15 mg l−1 saquinavir (n = 20). Spiked protein/plasma solutions were dialyzed against isotonic phosphate buffer, at 37 °C. At equilibrium, indinavir and saquinavir concentrations were quantified, and the fu determined.Results: Indinavir and saquinavir demonstrated protein concentration‐dependent binding in buffer solutions of HSA and AAG. Indinavir fu was significantly higher in umbilical cord (0.53 ± 0.12) compared with maternal (0.36 ± 0.11) plasma (95% CI of the difference −0.26, −0.097). Similarly, saquinavir fu was different between umbilical cord (0.0090 ± 0.0046) and maternal plasma (0.0066 ± 0.0039) (95% CI of the difference −0.0032, −0.0016). The transplacental AAG concentration gradient contributed significantly to the binding differential of both drugs.Conclusions: The differential plasma binding of both drugs, which was largely the result of the transplacental AAG concentration gradient, would contribute to the low C : M total plasma concentration ratios observed previously. Unbound concentrations of indinavir and saquinavir are likely to be substantially lower in umbilical cord than maternal plasma.Keywords
This publication has 33 references indexed in Scilit:
- Differential Bidirectional Transfer of Indinavir in the Isolated Perfused Human PlacentaAntimicrobial Agents and Chemotherapy, 2005
- Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virusAmerican Journal of Obstetrics and Gynecology, 2004
- Drug Transfer and Metabolism by the Human PlacentaClinical Pharmacokinetics, 2004
- HIV-1 Protease InhibitorsClinical Infectious Diseases, 2000
- Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposureJournal of Clinical Investigation, 1999
- Differential Binding of Warfarin to Maternal, Foetal and Non-pregnant Sera and its Clinical ImplicationsJournal of Pharmacy and Pharmacology, 1996
- Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus TherapyThe Journal of Infectious Diseases, 1995
- Plasma Protein Binding of Drugs in Pregnancy and in NeonatesClinical Pharmacokinetics, 1990
- The Significance of Plasma Protein Binding on the Fetal/Maternal Distribution of Drugs at Steady-StateClinical Pharmacokinetics, 1988
- Plasma Protein Binding of Drugs in PregnancyClinical Pharmacokinetics, 1982